Phase 4
Completed N=30
Mechanisms of Weight Loss With SGLT2 Inhibition
Source: ClinicalTrials.gov NCT02360774 ↗Enrolled (actual)
30
Serious AEs
12.0%
Results posted
Aug 2018
Primary outcomePrimary: Change in Body Weight — 3.0; 0.3 kg
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to investigate the effect of canagliflozin, a medication approved by the FDA for the treatment of type 2 diabetes, on body weight and metabolism in people with type 2 diabetes who are overweight or obese.
Canagliflozin lowers glucose levels in the blood by making the kidneys excrete, rather than absorb, glucose. Canagliflozin is also often associated with weight loss.
The study population will generally be type 2 diabetics, ages 18-75 years old, who are overweight or obese.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Body Weight |
3.0; 0.3 | — |
| SECONDARY Change in Resting Energy Expenditure, Measured Using Indirect Calorimetery |
-60.8; -68.6 | — |
| SECONDARY Change in Body Composition, Measured Using DXA Scanning. |
-0.2; -0.4 | — |
| SECONDARY Change in Glycemic Control |
-0.4; -0.1 | — |
Eligibility Criteria
Inclusion Criteria
- Type 2 diabetes
- BMI 25-45 kg/m2
- Hemoglobin A1C > 6.5% but 60)
- Age 18-75
Exclusion Criteria
- Type 1 diabetes
- History of recurrent UTI or mycotic genital infections
- Treatment with insulin or a GLP1 agent
- Pregnant or breastfeeding
Data sourced from ClinicalTrials.gov (NCT02360774). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.